MetaCap

Lantheus (LNTH) vs QuidelOrtho (QDEL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lantheus (LNTH) has outperformed QuidelOrtho (QDEL) over the past year, gaining 82.9% versus a loss of 65.8%. Over five years, LNTH leads with a +266.1% price change compared with -94.3% for QDEL. Lantheus is the larger company by market cap ($6.68 billion vs $570.9 million), about 11.7 times the size.

On valuation, QuidelOrtho trades at a lower forward P/E (6.3x vs 15.3x for Lantheus). Lantheus converts more of its revenue into profit, with a net margin of 15.2% versus -41.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LNTH+82.91%QDEL-65.83%
+107%+16%-74%
Nov 21, 20251 yearNov 20, 2026
LNTH+255.87%QDEL-94.54%
+351%+118%-116%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LNTH versus QDEL key metrics
MetricLNTHQDEL
Share price$102.10$8.32
Market cap$6.68B$570.86M
1-day change0.00%-6.73%
YTD return+53.42%-70.87%
1-year return+82.91%-65.83%
5-year return+266.08%-94.25%
P/E ratio (TTM)25.40—
Forward P/E15.346.32
EPS (TTM)$4.02$-5.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.54B$2.73B
Revenue growth (YoY)+0.50%-1.89%
Net income (latest FY)$233.56M$-1.13B
Gross margin61.10%46.67%
Operating margin20.16%-33.67%
Net margin15.15%-41.45%
52-week high$111.86$35.58
52-week low$54.94$8.06
Distance from 52-week high-8.73%-76.62%
Analyst consensusholdhold
Avg. price target upside+3.81%+80.29%
Average volume1.02M2.04M
Shares outstanding65.40M68.61M
Employees1,1936,500
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Lantheus is about 11.7 times larger than QuidelOrtho by market value ($6.68B vs $570.86M).
  • LNTH has outperformed QDEL by 148.7 percentage points over the past year.
  • Lantheus is more profitable, keeping 15.2 cents of every revenue dollar as net income versus -41.5 cents for QuidelOrtho.

About Lantheus

LNTH stock →

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees

About QuidelOrtho

QDEL stock →

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 6,500 employees

LNTH vs QDEL FAQ

Which is bigger, Lantheus or QuidelOrtho?

Lantheus (LNTH) is larger, with a market capitalization of $6.68B compared with $570.86M for QuidelOrtho (QDEL).

Which stock has performed better over the past year, LNTH or QDEL?

LNTH returned +82.91% over the past 12 months, compared with -65.83% for QDEL (price return, excluding dividends). Past performance does not predict future results.

Are Lantheus and QuidelOrtho in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons